Drug intelligence / Profile preview

LZM002C

Development stage: Unknown
Lead developer: Livzon Monoclonal Antibody
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**LZM002C** is an investigational recombinant human-murine chimeric monoclonal antibody directed against CD20, developed by Livzon MABPharm as a biosimilar candidate to rituximab. In the registered Chinese Phase 1 study CTR20171007, intravenous LZM002C was compared with MabThera for pharmacokinetic, pharmacodynamic, safety, tolerability, and immunogenicity similarity in patients with CD20-positive B-cell non-Hodgkin lymphoma. By binding CD20 on B cells, it is intended to deplete CD20-positive B cells through rituximab-like immune-mediated cytolytic mechanisms, including antibody-dependent cellular cytotoxicity. ([yscro.com](https://www.yscro.com/index.php/cde/63df10279088a806877a92de50606e28.html))

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on LZM002C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LZM002C.

Explore the full profile